24 completed, 5 unknown, 3 terminated, 1 recruiting. 11 Not applicable, 9 Phase 4, 5 Phase 3, 3 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 11 | Completed 6, Unknown 3, Terminated 2 |
| Phase 4 | 9 | Completed 7, Unknown 2 |
| Phase 3 | 5 | Completed 5 |
| Phase 1 | 3 | Completed 2, Terminated 1 |
| Phase 2 | 2 | Completed 1, Recruiting 1 |
Follow pegvisomant: new trials by email Literature Review of pegvisomant trials Research Report on pegvisomant
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Growth Hormone Inhibition Using Pegvisomant in Severe Insulin Resistance Pegvisomant - Insulin Receptor Mutation, Partial Lipodystrophy | Phase 2 | Recruiting | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 25 | 2023-01-23 | 2026-08-18 |
| Korean Regulatory Post Marketing Surveillance for Somavert Somavert - Acromegaly | Completed | Pfizer | 11 | 2022-07-13 | 2026-07-23 | |
| Growth Hormone as a Model for Reversible Activation of Adipose Tissue Fibrosis Growth hormone, saline and GH receptor blockade (Pegvisomant) - Fibrosis | Not applicable | Unknown | University of Aarhus | 10 | 2021-08-01 | 2023-05-30 |
| Safety and Efficacy of Pegvisomant in Children With Growth Hormone Excess Pegvisomant - Pituitary Disease | Phase 3 | Completed | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | 12 | 2019-10-21 | 2025-11-06 |
| Strict IGF-1 Control in Acromegaly Pegvisomant - Acromegaly | Phase 3 | Completed | Unity Health Toronto | 10 | 2017-07-27 | 2021-11-22 |
| Bone MicroArchitecture in Acromegaly Pegvisomant - Acromegaly, Osteoporosis Risk | Completed | Columbia University | 77 | 2016-08-03 | 2021-07-13 | |
| Lipolytic Effects of GH in Human Subjects in Vivo Growth Hormone, Pegisomant - Metabolic Diseases, Growth Hormone Treatment | Not applicable | Completed | University of Aarhus | 9 | 2016-05-30 | 2020-03-26 |
| Pasireotide LAR and Pegvisomant Study in Acromegaly Pasireotide LAR 60 mg, Pegvisomant - Acromegaly | Phase 4 | Unknown | Erasmus Medical Center | 60 | 2015-08-01 | 2016-08-03 |
| Substrate Metabolism, Growth Hormone Signaling, and Insulin Sensitivity During Fasting Fasting, Saline, Pegvisomant - Healthy | Not applicable | Completed | University of Aarhus | 10 | 2015-07-01 | 2016-11-23 |
| Role of Growth Hormone Antagonism in Modulating Insulin Sensitivity in Subjects With Pre-diabetes pegvisomant - Diabetes, Metabolic Syndrome | Phase 2 | Completed | University of California, San Francisco | 6 | 2014-01-01 | 2017-04-24 |
| A Relative Bioavailability Study To Evaluate Safety, Tolerability And Pharmacokinetic Comparability Of Pegvisomant 1 X 30 Mg Vs 2 X 15 Mg Subcutaneously Administered In Healthy Subjects 1 x 30 mg/mL pegvisomant, 2 x 15 mg/mL pegvisomant - Healthy Volunteers | Phase 1 | Completed | Pfizer | 17 | 2013-08-01 | 2013-12-12 |
| Effect of DPP4 Inhibition on Growth Hormone Secretion Sitagliptin, Pegvisomant, Placebo - Obesity | Phase 4 | Completed | Vanderbilt University | 44 | 2013-01-01 | 2018-05-29 |
| Acromegaly Combination Treatment Study Pegvisomant, Octreotide LAR, Lanreotide - Acromegaly | Not applicable | Terminated | Cedars-Sinai Medical Center | 76 | 2012-03-29 | 2023-01-04 |
| Pegvisomant With Glucagon Test to Assess for Adult Growth Hormone Deficiency Pegvisomant, Regular insulin - Adults Growth Hormone Deficiency. | Not applicable | Unknown | Oregon Health and Science University | 10 | 2011-03-01 | 2013-10-24 |
| Tissue Biomarker for Pegvisomant Action Pegvisomant - Acromegaly | Not applicable | Completed | Cedars-Sinai Medical Center | 8 | 2010-11-01 | 2017-08-22 |
| Safety, Tolerability and Relative Bioavailability of Pegvisomant in Healthy Subjects pegvisomant - Bioavailability | Phase 1 | Completed | Pfizer | 14 | 2010-10-01 | 2012-01-05 |
| Figitumumab Combined With Pegvisomant For Advanced Solid Tumors figitumumab, pegvisomant - Colorectal Neoplasms, Lung Neoplasms | Phase 1 | Terminated | Pfizer | 24 | 2009-11-01 | 2013-12-13 |
| The Relationship Between the Growth Hormone (GH)- Insulin Like Growth Factor I (IGF-I) System and the Inflammatory System in Healthy Normal Persons Somatropin, Pegvisomant - Interaction Between the GH/IGF-I System and the Immune-system | Not applicable | Unknown | Herlev Hospital | 12 | 2009-09-01 | 2009-09-01 |
| Co-treatment With Pegvisomant and a Somatostatin Analogue (SA) in SA-responsive Acromegalic Patients Pegvisomant, Somatostatin analog (lanreotide or octreotide) - Acromegaly, Insulin Resistance | Not applicable | Completed | University of Aarhus | 18 | 2008-06-01 | 2012-01-26 |
| Acute Application of Pegvisomant and Octreotide in Acromegaly pegvisomant, combination with somatostatin analogue octreotide, combination with dopamine agonist cabergoline - Acromegaly | Phase 4 | Completed | Ludwig-Maximilians - University of Munich | 10 | 2008-01-01 | 2008-04-01 |
Showing 20 of 33. Sign in to see all of them.
Acromegaly (18) · Insulin Resistance (6) · Pituitary Diseases (2) · Adenoma (1) · Brain Neoplasms (1) · Breast Neoplasms (1) · Cardiomegaly (1) · Colorectal Neoplasms (1) · Diabetes Mellitus (1) · Dwarfism, Pituitary (1) · Fasting (1) · Fatty Liver (1) · Fibrosis (1) · Fibrous Dysplasia, Polyostotic (1) · Gigantism (1)
Pfizer (8) · University of Aarhus (6) · Cedars-Sinai Medical Center (2) · Erasmus Medical Center (2) · Novartis Pharmaceuticals (2) · Columbia University (1) · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (1) · Herlev Hospital (1) · Ipsen (1) · Ludwig-Maximilians - University of Munich (1) · National Institute of Dental and Craniofacial Research (NIDCR) (1) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (1) · Oregon Health and Science University (1) · The Christie NHS Foundation Trust (1) · Unity Health Toronto (1)
United States (12) · Denmark (8) · Germany (7) · Canada (4) · France (4) · Italy (4) · United Kingdom (4) · Netherlands (3) · Spain (3) · Australia (2) · Brazil (2) · Greece (2) · Norway (2) · Sweden (2) · Belgium (1)
Shlomo Melmed, MD (2) · Bruno Allolio, MD (1) · Constance Chik, MD (1) · Ethan J Weiss, MD (1) · Jessica K Devin, MD, MSCI (1) · Jochen Schopohl, MD (1) · Karim A Calis, Pharm.D. (1) · Kathleen Mulligan, PhD (1)
PMID 17492951, PMID 18460563, PMID 19820031, PMID 20731625, PMID 21148630, PMID 23785020, PMID 26496767, PMID 29155991, PMID 29478970, PMID 31668393, PMID 31724339, PMID 32754748
2005 (1), 2014 (1), K23HL119602 (1)